Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lazertinib - Janssen Biotech/Yuhan

Drug Profile

Lazertinib - Janssen Biotech/Yuhan

Alternative Names: C-18112003-G; GNS 1480; JNJ 73841937; JNJ-1937; JNJ-73841937-AAA; Lazertinib mesylate monohydrate; Leclaza; YH-25448

Latest Information Update: 22 Jun 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Oscotec
  • Developer Janssen Biotech; Memorial Sloan-Kettering Cancer Center; Yuhan
  • Class Amides; Aniline compounds; Antineoplastics; Dimethylamines; Ethers; Morpholines; Pyrimidines; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer

Most Recent Events

  • 14 Jun 2022 Phase-II clinical trials in Non-small cell lung cancer in South Korea (PO) (NCT05338619)
  • 08 Jun 2022 Janssen Research & Development plans a phase III trial in Non-small cell lung cancer (Combination therapy, Second-line therapy or greater, Metastatic disease, Late-stage disease), in Argentina, Brazil, Canada, China, France, Israel, Italy, Malaysia, Poland, Spain, Taiwan, Turkey and in the US, In August 2022, (PO)(NCT05388669) (EudraCT2022-000525-25)
  • 03 Jun 2022 Efficacy and adverse events data from a phase Ib CHRYSALIS-2 trial in Non-small cell lung cancer presented at the 58th Annual Meeting of the American Society of Clinical Oncology (ASC0-2022)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top